Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

AstraZeneca signs $6bn worth cancer asset deal with Daiichi Sankyo

pharmaceutical-technologyJuly 28, 2020

Tag: AstraZeneca , Daiichi Sankyo , DS-1062

PharmaSources Customer Service